Nice job on the PFE/Tremelimumab quiz! When PFE out-licensed Tremelimumab to AZN in 2011 (#msg-67624944), PFE retained the right to use Tremelimumab in certain undisclosed combination regimens. On the recent Leerink webcast, PFE confirmed that use of Tremelimumab with a cancer vaccine was one of the retained uses.
How much research, if any, did you have to do to knwow the answer?
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.